•  
  •  
 

Abstract

Background

Obesity is a prevalent health issue that affects people of all ages at a high rate. Tirzepatide (TZP) is a hypoglycemic medication that acts as a dual antagonist for both the GIP-1 and GIP receptors. Previous reports have shown that TZP treatment demonstrated substantial weight reduction as well as lipid-modulating effects in obese and overweight individuals.

Objective

The aim from this study is to examine the potential protective effect of TZP on oxidative stress status and HFD induced obesity in male rats.

Methods

This research employed a total of 28 adult male Sprague-Dawley rats. Normal control group involved seven rats fed a regular diet, while the other rats received a high-fat diet (HFD). Obese rats separated into three groups after eight weeks of HFD: obesity, tirzepatide (10 nmol/kg) s.c, and vehicle groups, and treated for four weeks. Data regarding body weight, blood glucose, and lipid profile, as well as the levels of SOD and MDS in the liver tissue were obtained.

Results

The results have demonstrated that TZP-treated obese rats exhibited significantly reduced body weight, blood glucose levels, TG and VLDL. Additionally, liver specimens from TZP group showed increased content of SOD enzyme compared to obese untreated rats.

Conclusion

Treating obese rats with TZP improved body weight, blood glucose lipid profile and elevating the level of the antioxidant defense.

References

References

[1] Aguilar Cordero MJ, Gonzalez Jimenez E, García García CJ, García Lopez PA, Alvarez Ferre J, Padilla Lopez CA, et al. Obesity in a school children population from granada: assessment of the efficacy of an educational intervention. Nutr Hosp 2011;26(3):636-41.

[2] Gonzalez Jimenez E. ACMJ, GGCJ, AFJG lopez PA,. prevalence of overweight and nutritional obesity and high blood pressure and its relationship with anthropometric indicators in a school population in Granada and its province. Hosp Nutr. 2011;26(5).

[3] Romero-Ibarguengoitia ME, Vadillo-Ortega F, Caballero AE, Ibarra-Gonzalez I, Herrera-Rosas A, Serratos-Canales MF, et al. Family history and obesity in youth, their effect on acylcarnitine/aminoacids metabolomics and non-alcoholic fatty liver disease (NAFLD). Structural equation modeling approach. PLoS One 2018 Feb 1;13(2).

[4] Corica D, Aversa T, Valenzise M, Messina MF, Alibrandi A, De Luca F, et al. Does family history of obesity, cardiovascular, and metabolic diseases influence onset and severity of childhood obesity? Front Endocrinol 2018 May 2;9(MAY).

[5] Sirtori A BACPBMV v. CSLMRAIO group. ICF-OB: a multidisciplinary questionnaire based on the international classification of functioning, disability and health to address disability in obesity. Eur J Phys Rehabil Med 2018 Feb 1;54(1).

[6] Razzak H, El-Metwally A, Harbi A, Al-Shujairi A, Qawas A. The prevalence and risk factors of obesity in the United Arab Emirates. Saudi J. Obes. 2017;5(2):57.

[7] Hruby A, Manson JAE, Qi L, Malik VS, Rimm EB, Sun Q, et al. Determinants and consequences of obesity. Am J Publ Health 2016;106:1656-62. American Public Health Association Inc.

[8] Waterland RA. Epigenetic epidemiology of obesity: application of epigenomic technology. In: Nutrition reviews; 2008.

[9] Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab 2021 Feb 1;106(2): 388-96.

[10] Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Available from: https:// doi.org/10.1007/s00125-022-05715-4.

[11] Adriaenssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, Girish M, et al. Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metabol 2019 Nov 5; 30(5):987-996.e6.

[12] Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules 2022;27. MDPI.

[13] Bray JJH, Foster-Davies H, Salem A, Hoole AL, Obaid DR, Halcox JPJ, et al. Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metabol 2021 Aug 1;23(8): 1806-22.

[14] Pereira-Lancha LO, Campos-Ferraz PL, Lancha AH. Obesity: considerations about etiology, metabolism, and the use of experimental models. Diab Metabol Syndr Obes 2012;5: 75-87. Dove Medical Press Ltd.

[15] Von Diemen V, Trindade EN, Roberto M, Trindade M. Experimental model to induce obesity in rats 1 Modelo experimental para induzir obesidade em ratos. Vol. 21, Acta Cir Bras.

[16] Hariri N, Thibault L. High-fat diet-induced obesity in animal models. Nutr Res Rev 2010 Dec;23(2):270-99.

[17] Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005 May 2;115(5):1111-9.

[18] Internet]. 2005. Available from: www.nature.com/nature.

[19] Boden G. Obesity and free fatty acids. Vol. 37. Endocrinol Metab Clin N Am 2008:635-46.

[20] Boden G, Cheung P, Peter Stein T, Kresge K, Mozzoli M. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol Endocrinol Metab 2002;283(1 46-1).

[21] Boden G, Jadali F, White J, Liang Y, Mozzoll M, Chen X, et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men.

[22] Gutierrez DA, Puglisi MJ, Hasty AH. Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia.

[23] Lenzi A. Endocrinology series

Internet]. Available from: http://www.springer.com/series/14021.

[24] Cho Y, Lee SG, Jee SH, Kim JH. Hypertriglyceridemia is a major factor associated with elevated levels of small dense LDL cholesterol in patients with metabolic syndrome. Ann Lab Med 2015 Nov 1;35(6):586-94.

[25] Parra ES, Urban A, Panzoldo NB, Nakamura RT, Oliveira R, De Faria EC. A reduction of CETP activity, not an increase, is associated with modestly impaired postprandial lipemia and increased HDL-Cholesterol in adult asymptomatic women. Lipids Health Dis 2011;10.

[26] Amin KA, Nagy MA. Effect of Carnitine and herbal mixture extract on obesity induced by high fat diet in rats. Diabetol Metab Syndrome 2009 Oct 16;1(1).

[27] Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. In: Journal of clinical endocrinology and metabolism; 2004. p. 2595-600.

[28] Leopold JA, Loscalzo J. Oxidative mechanisms and atherothrombotic cardiovascular disease. Drug Discov Today Ther Strat 2008;5:5-13.

[29] ARYA101261291753800.

[30] Lechleitner M, Koch T, Herold M, Dzien A, Hoppichler F. Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Intern Med 2000; 248(1):67-76.

[31] Seo H, Lee NH, Ryu S. Antioxidant and antiapoptotic effects of pine needle powder ingestion and endurance training in high cholesterol-fed rats. J Exerc Nutrition Biochem 2014 Sep;18(3):301-9.

[32] Noeman SA, Hamooda HE, Baalash AA. Biochemical study of oxidative stress markers in the liver, kidney and heart of high fat diet induced obesity in rats. Diabetol Metab Syndrome 2011;3(1).

[33] Kumar P, Bhandari U, Jamadagni S. Fenugreek seed extract inhibit fat accumulation and ameliorates dyslipidemia in high fat diet-induced obese rats. BioMed Res Int 2014;2014.

[34] Frias JP, Bastyr EJ, Vignati L, Tsch€op MH, Schmitt C, Owen K, et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metabol 2017 Aug 1;26(2):343-352.e2.

[35] NamKoong C, Kim MS, Jang BT, Lee YH, Cho YM, Choi HJ. Central administration of GLP-1 and GIP decreases feeding in mice. Biochem Biophys Res Commun 2017 Aug 19;490(2): 247-52.

[36] Adriaenssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, Girish M, et al. Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metabol 2019 Nov 5; 30(5):987-996.e6.

[37] Parton LE, Ye CP, Coppari R, Enriori PJ, Choi B, Zhang CY, et al. Glucose sensing by POMC neurons regulates glucose homeostasis and is impaired in obesity. Nature 2007 Sep 13; 449(7159):228-32.

[38] Kim KS, Seeley RJ, Sandoval DA. Signalling from the periphery to the brain that regulates energy homeostasis. Nat Rev Neurosci 2018;19:185-96. Nature Publishing Group.

[39] Kim SJ, Nian C, Karunakaran S, Clee SM, Isales CM, McIntosh CHS. GIP-Overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One 2012 Jul 3;7(7).

[40] Lv X, Wang H, Chen C, Zhao Y, Li K,Wang Y, et al. The effect of tirzepatide on weight, lipid metabolism and blood pressure in overweight/obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diab Metabol Syndr Obes 2024;17:701-14. Dove Medical Press Ltd.

[41] Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004 Dec 15; 114(12):1752-61.

[42] Chen Y, na Xu Y, yu Ye C, bo Feng W, tong Zhou Q, Yang D hua, et al. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis. Vol. 43. Acta Pharmacol Sin 2022:1156-66. Springer Nature.

[43] Tariq Z,Green CJ, Hodson L.Are oxidative stressmechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?, vol. 34. Liver International: Blackwell Publishing Ltd; 2014.

[44] Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132(6):2131-57.

[45] Kim JS, Diebold BA, Babior BM, Knaus UG, Bokoch GM. Regulation of Nox 1 activity via protein kinase A-mediated phosphorylation of NoxA 1 and 14-3-3 binding. J Biol Chem 2007 Nov 30;282(48):34787-800.

[46] Batchuluun B, Inoguchi T, Sonoda N, Sasaki S, Inoue T, Fujimura Y, et al. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKCNAD( P)H oxidase pathway in human aortic endothelial cells. Atherosclerosis 2014 Jan;232(1):156-64.

[47] Turkseven S, Kruger A, Mingone CJ, Kaminski P, Inaba M, Rodella LF, et al. Antioxidant mechanism of heme oxygenase- 1 involves an increase in superoxide dismutase and catalase in experimental diabetes. Am J Physiol Heart Circ Physiol 2005 Aug;289(2 58-2).

[48] Batiha GES, Al-kuraishy HM, Al-Gareeb AI, Ashour NA, Negm WA. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach. Vol. 31, inflammopharmacology. Springer science and business media deutschland GmbH. 2023. p. 1683-93.

[49] Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. In: Diabetes care. American Diabetes Association Inc.; 2020. p. 1352-5.

Download

Share

COinS